EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Cardiovascular Burden of the V142I Transthyretin Variant

Senthil Selvaraj, Brian Claggett, Svati H Shah, Robert J Mentz, Michel G Khouri, Ani W Manichaikul, Sadiya S Khan, Stephen S Rich, Thomas H Mosley, Emily B Levitan, Pankaj Arora, Parag Goyal und 7 weitere

JAMA · 2024

DOI: 10.1001/jama.2024.4467 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift JAMA, 2024. Verfasst von Senthil Selvaraj und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina. Hauptthemen laut MEDLINE: Amyloidosis, Black or African American, Cardiomyopathies, Heart Failure. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Individual cohort studies concur that the amyloidogenic V142I variant of the transthyretin ( TTR ) gene, present in 3% to 4% of US Black individuals, increases heart failure (HF) and mortality risk. Precisely defining carrier risk across relevant clinical outcomes and estimating population burden of disease are important given established and emerging targeted treatments.

Objectives

To better define the natural history of disease in carriers across mid to late life, assess variant modifiers, and estimate cardiovascular burden to the US population. Design, Setting, and Participants A total of 23 338 self-reported Black participants initially free from HF were included in 4 large observational studies across the US (mean [SD], 15.5 [8.2] years of follow-up). Data analysis was performed between May 2023 and February 2024. Exposure V142I carrier status (n = 754, 3.2%). Main Outcomes and Measures Hospitalizations for HF (including subtypes of reduced and preserved ejection fraction) and all-cause mortality. Outcomes were analyzed by generating 10-year hazard ratios for each age between 50 and 90 years. Using actuarial methods, mean survival by carrier status was estimated and applied to the 2022 US population using US Census data.

Results

Among the 23 338 participants, the mean (SD) age at baseline was 62 (9) years and 76.7% were women. Ten-year carrier risk increased for HF hospitalization by age 63 years, predominantly driven by HF with reduced ejection fraction, and 10-year all-cause mortality risk increased by age 72 years. Only age (but not sex or other select variables) modified risk with the variant, with estimated reductions in longevity ranging from 1.9 years (95% CI, 0.6-3.1) at age 50 to 2.8 years (95% CI, 2.0-3.6) at age 81. Based on these data, 435 851 estimated US Black carriers between ages 50 and 95 years are projected to cumulatively lose 957 505 years of life (95% CI, 534 475-1 380 535) due to the variant. Conclusions and Relevance Among self-reported Black individuals, male and female V142I carriers faced similar and substantial risk for HF hospitalization, predominantly with reduced ejection fraction, and death, with steep age-dependent penetrance. Delineating the individual contributions of, and complex interplay among, the V142I variant, ancestry, the social construct of race, and biological or social determinants of health to cardiovascular disease merits further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AmyloidosisBlack or African AmericanCardiomyopathiesHeart FailureAgedAged, 80 and overFemaleHumansMaleMiddle AgedDisease ProgressionHeterozygoteHospitalizationPrealbuminStroke VolumeUnited StatesCost of Illness

Substanzen

PrealbuminTTR protein, human

Autor:innen und Institutionen

  • Division of Cardiology, Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Duke Molecular Physiology Institute, Durham, North Carolina.
  • Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
  • Center for Public Health Genomics, University of Virginia, Charlottesville.
  • Division of Cardiology, Department of Medicine and Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
  • The MIND Center, University of Mississippi Medical Center, Jackson.

Förderung

  • NINDS NIH HHS
  • NHLBI NIH HHS
  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NHGRI NIH HHS

Zitieren

APA

Selvaraj, S., Claggett, B., Shah, S. H., Mentz, R. J., Khouri, M. G., Manichaikul, A. W., Khan, S. S., Rich, S. S., Mosley, T. H., Levitan, E. B., Arora, P., Goyal, P., Haring, B., Eaton, C. B., Cheng, R. K., Wells, G. L., Manson, J. E., Fontana, M., & Solomon, S. D. (2024). Cardiovascular Burden of the V142I Transthyretin Variant. JAMA. https://doi.org/10.1001/jama.2024.4467

Vancouver

Selvaraj S, Claggett B, Shah SH, Mentz RJ, Khouri MG, Manichaikul AW, et al. Cardiovascular Burden of the V142I Transthyretin Variant. JAMA. 2024. doi:10.1001/jama.2024.4467

BibTeX
@article{Selvaraj2024,
  author = {Selvaraj, Senthil and Claggett, Brian and Shah, Svati H and Mentz, Robert J and Khouri, Michel G and Manichaikul, Ani W and Khan, Sadiya S and Rich, Stephen S and Mosley, Thomas H and Levitan, Emily B and Arora, Pankaj and Goyal, Parag and Haring, Bernhard and Eaton, Charles B and Cheng, Richard K and Wells, Gretchen L and Manson, JoAnn E and Fontana, Marianna and Solomon, Scott D},
  title = {Cardiovascular Burden of the V142I Transthyretin Variant},
  journal = {JAMA},
  year = {2024},
  doi = {10.1001/jama.2024.4467}
}
Kostenlos starten →